Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: XEQUEL BIO, INC.
Awarding agency: Department of Defense / Department of the Army
Funding agency: Department of Defense / Department of the Army
Period of performance: 2017-09-25 to 2022-09-27
Current total value of award: $999960.15
Description: ARMY SBIR MEDICAL R&D CONTRACT FOR "PROPOSAL A2-6647 TITLED, "A NOVEL PEPTIDE-BASED TOPICAL THERAPEUTIC TO PROMOTE CORNEAL REGENERATION AND RESTORE CORNEAL BIOMECHANICS FOLLOWING BLAST AND BURN INJURIES" FIRSTSTRING RESEARCH, INC HAS BEEN ACQUIRED BY XEQUEL BIO. INC.